Brain hemorrhage is the most fatal form of stroke. For patients with both intracerebral (ICH) and intraventricular (IVH) hemorrhages, community mortality is consistently reported at 50-80% with no validated, efficacious treatment. Animal models demonstrate substantial physiologic and functional benefit when blood is removed rapidly from the ventricle;our human trial data show similar mortality and functional benefit trends with blood removal. Current therapy which uses extraventricular drainage (EVD) neither improves long-term survival nor alters the effect of blood on tissue. Adding recombinant tissue plasminogen activator (rt-PA) may be the key to a rapid, effective, and safe means for blood removal that limits brain tissue injury, increasing the effectiveness of EVD's in removing blood and perhaps controlling ICP. If validated by a clinical trial, our therapy would offer the first-ever clinically directive intervention for this lethal disease. We seek support for a Phase III RCT trial using EVD and rt-PA as IVH treatment. New human safety and dose-finding data demonstrate the concept that rapid removal of IVH clot can be associated with clinically important improvements in morbidity and mortality (>45% mRS 0-3). This is a strong signal that we can translate IVH animal models to human treatment with robust beneficial effects on level of consciousness, ICU treatment intensity, survival, and lowered neurologic morbidity burden as measured by functional performance. The literature, our data, and prior NINDS ICH and NINDS health disparities reviews, support the need for a pivotal Phase III trial, investigating the benefits of removal of IVH clot by comparing use of EVD plus rt-PA vs. EVD alone. We can potentially save lives and improve outcome of brain hemorrhage survivors which now disproportionally burdens minorities, women and the elderly. This trial has robust potential to add an average of 1.7 Qualy's per subject treated making the economic impact substantial. Once we provide critical evidence, generalization to a wide range of hospitals, using SPOTRIAS and newer networks, would be technically straightforward as the interventions and expertise to perform this therapy are already widespread. The planning grant has supported a smooth transition from our completed Phase II trials to the definitive Phase III trial. We are now fully operational and in position to perform without delay in early 2009.
Brain hemorrhage is the most fatal form of stroke with a 50-80% mortality rate in patients with both ICH and IVH hemorrhage extension. This disease disproportionately burdens minorities, women and the elderly. Dose finding and human safety data demonstrate that when a clot is removed rapidly from the ventricle using an EVD and rt-PA administration as treatment, functional and physiologic benefits can be seen (good mRS 0-3 >45%). If the clinical trial we propose validates our theory it would offer the first-ever clinically directive intervention for this lethal disease, potentially saving lives and improving the functional outcomes of brain hemorrhage survivors including their quality of life.
|Rivera-Lara, Lucia; Murthy, Santosh B; Nekoovaght-Tak, Saman et al. (2018) Influence of Bleeding Pattern on Ischemic Lesions After Spontaneous Hypertensive Intracerebral Hemorrhage with Intraventricular Hemorrhage. Neurocrit Care 29:180-188|
|Müller, Achim; Mould, W Andrew; Freeman, W David et al. (2018) The Incidence of Catheter Tract Hemorrhage and Catheter Placement Accuracy in the CLEAR III Trial. Neurocrit Care 29:23-32|
|Lane, Karen; Keita, Maningbe; Avadhani, Radhika et al. (2018) African American Screening and Enrollment in (Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage III) CLEAR III. Clin Res (Alex) 32:|
|Ullman, Natalie L; Tahsili-Fahadan, Pouya; Thompson, Carol B et al. (2018) Third Ventricle Obstruction by Thalamic Intracerebral Hemorrhage Predicts Poor Functional Outcome Among Patients Treated with Alteplase in the CLEAR III Trial. Neurocrit Care :|
|Baker, Alexandra Delaney; Rivera Perla, Krissia Margarita; Yu, Zhiyuan et al. (2018) Fibrinolytic for treatment of intraventricular hemorrhage: A meta-analysis and systematic review. Int J Stroke 13:11-23|
|Fam, Maged D; Stadnik, Agnieszka; Zeineddine, Hussein A et al. (2018) Symptomatic Hemorrhagic Complications in Clot Lysis: Evaluation of Accelerated Resolution of Intraventricular Hemorrhage Phase III Clinical Trial (CLEAR III): A Posthoc Root-Cause Analysis. Neurosurgery 83:1260-1268|
|Fam, Maged D; Zeineddine, Hussein A; Eliyas, Javed Khader et al. (2017) CSF inflammatory response after intraventricular hemorrhage. Neurology 89:1553-1560|
|Hanley, Daniel F; Lane, Karen; McBee, Nichol et al. (2017) Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet 389:603-611|
|Muschelli, John; Sweeney, Elizabeth M; Ullman, Natalie L et al. (2017) PItcHPERFeCT: Primary Intracranial Hemorrhage Probability Estimation using Random Forests on CT. Neuroimage Clin 14:379-390|
|Fam, Maged D; Pang, Alice; Zeineddine, Hussein A et al. (2017) Demographic Risk Factors for Vascular Lesions as Etiology of Intraventricular Hemorrhage in Prospectively Screened Cases. Cerebrovasc Dis 43:223-230|
Showing the most recent 10 out of 53 publications